RedHill Biopharma (NASDAQ:RDHL) Now Covered by StockNews.com

StockNews.com started coverage on shares of RedHill Biopharma (NASDAQ:RDHL) in a research report report published on Thursday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

RedHill Biopharma Price Performance

Shares of RedHill Biopharma stock opened at $0.42 on Thursday. The business has a 50-day moving average price of $0.41 and a 200 day moving average price of $0.47. RedHill Biopharma has a fifty-two week low of $0.26 and a fifty-two week high of $3.28.

Institutional Trading of RedHill Biopharma

An institutional investor recently raised its position in RedHill Biopharma stock. Gagnon Securities LLC increased its position in RedHill Biopharma Ltd. (NASDAQ:RDHL) by 32.1% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 118,360 shares of the biotechnology company’s stock after acquiring an additional 28,771 shares during the period. Gagnon Securities LLC owned approximately 0.40% of RedHill Biopharma worth $63,000 at the end of the most recent reporting period. 7.20% of the stock is currently owned by hedge funds and other institutional investors.

About RedHill Biopharma

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.